Results presented at the European League Against Rheumatism Annual Congress have confirmed that Systemic Lupus Erythematosus can increase the risk of developing cervical cancer in women.
Results presented at the European League Against Rheumatism Annual Congress have confirmed that Systemic Lupus Erythematosus (SLE) can increase the risk of developing cervical cancer in women, with the highest risk identified in women treated with immunosuppressive agents for SLE.
The study, which was conducted in Stockholm, evaluated data on women who were diagnosed with SLE between 2006 and 2012. The rate of cervical dysplasia or invasive cervical cancer in these women was double that of a matched general cohort. The authors adjusted the comparison for age, sex, education level, healthcare utilization, number of children, marital status, family history of cervical cancer, and prior cervical screening. Further, women with SLE who received systemic immunosuppressive agents were deemed at greater risk of cervical abnormalities.
According to Hjalmar Wadström, PhD, from the Karolinska Institute and lead investigator of the study, “Previous evidence that SLE or its treatment might increase the risk of cervical neoplasia has been inconclusive. Our findings have confirmed that SLE is a risk factor for cervical malignancies, even after adjusting for important risk determinants such as previous cervical screening.”
In the United States, incidence of SLE has been found to follow a distinct racial and geographical trend, with blacks more susceptible than whites. According to the CDC, annual incidence in 2002-2004 was higher for blacks in Michigan (7.9 vs 3.7 per 100,000 persons) and Georgia (9.4 vs 3.2 per 100,000 persons). Additionally, annual incidence for American Indians and Alaska natives was documented at 7.4 per 100,000 persons. Additionally, women are more susceptible then men.
Reference
Lupus confirmed as risk factor for cervical cancer: Women with lupus treated with immunosuppressives need regular cervical screening. ScienceDaily website. https://www.sciencedaily.com/releases/2016/06/160609115437.htm. Posted June 9, 2016. Accessed June 10, 2016.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More